Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENL101 for Relapsed/Refractory CD7+ Hematolymphoid Malignancies
NCT05398614Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SENL101 in t-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma, sponsored by Senlang Bio. Primary endpoint: Incidence and severity of adverse events at 24 months. Status: unknown.
02
Drugs
SENL101
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoma
Beyond the preview
Go deeper on NCT05398614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398614.